Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer
Titel:
Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer
Auteur:
Del Campo, J.M. Roszak, A. Bidzinski, M. Ciuleanu, T.E. Hogberg, T. Wojtukiewicz, M.Z. Poveda, A. Boman, K. Westermann, A.M. Lebedinsky, C.